Otsuka pays for European and Japanese voclosporin rights

18 December 2020

Otsuka Pharmaceutical (TYO: 4578) has acquired rights for the development and commercialization of oral voclosporin to treat lupus nephritis (LN) in the European Union (EU) and Japan as well as the UK, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine.

The Japanese drugmaker will pay Canada-headquartered firm Aurinia Pharmaceuticals (TSX:AUP) for the rights in exchange for $50 million in cash and up to $50 million in regulatory and reimbursement milestone payments.

"This collaboration will provide Aurinia with additional non-dilutive funds to focus on the successful US launch of voclosporin"Aurinia will also receive tiered royalties ranging from 10% to 20% on net sales on commercialization, along with additional milestone payments based on the attainment of certain annual sales by Otsuka.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK